| Health Briefing · The Hill Report Fatty Liver Disease Is Now Screened With a Four-Number Blood Score Since a 2023 renaming, the first check for liver scarring in people with metabolic risk factors is a calculation from age, two liver enzymes and a platelet count, followed by a stiffness scan when the score is not low. Connor Hill · InsightfulWord · October 10  | Key points | | Vomiting blood, black or tarry stools, new confusion or a change in alertness, abdominal swelling that is new or suddenly worse, or yellowing of the skin or eyes that is new or worsening quickly calls for emergency care. | | | In June 2023 international liver societies renamed the condition metabolic dysfunction-associated steatotic liver disease: fat in the liver plus at least one of five cardiometabolic risk factors. | | | The first-line screen, FIB-4, combines age, two liver enzymes and the platelet count. A score below 1.3 makes advanced scarring unlikely; above 2.67 makes it likely. | | | Two drugs carry accelerated approval for the inflammatory form with moderate to advanced scarring: resmetirom since March 14, 2024, and semaglutide since August 15, 2025. | | Liver fat rarely announces itself. The national digestive disease institute calls the condition "a silent disease with few or no symptoms," and estimates that about 24% of American adults have it. Because symptoms arrive late, the medical system relies on arithmetic. A routine metabolic panel and blood count already contain the inputs for the screening score, which is why guidance now asks clinicians to calculate it in people at risk rather than wait for complaints. | On the tape | Oct 5 A study of 25,736 community-dwelling adults at 18 locations in China, published in The Lancet Gastroenterology and Hepatology and highlighted by a sister review journal, found steatotic liver disease in 43.7% using a stiffness-and-fat scan, and liver stiffness of at least 8 kilopascals in 4.4%. Why it matters: the figures come from the baseline of a cohort, so they describe prevalence and point to metabolic dysfunction and alcohol as risk factors without proving cause in any individual. | | Oct 6 A post hoc analysis of a semaglutide obesity trial, presented at the European diabetes association's 2026 meeting, reported mean liver fat falling from 8.8% to 3.1% at week 72 in a 55-person imaging subgroup; 23 of 26 with baseline fat above 5% fell below it. Why it matters: liver outcomes were not prespecified and no placebo comparison was reported, so the result is exploratory. | | Oct 6 A drug developer announced three poster presentations for the American Association for the Study of Liver Diseases annual meeting, set for November 5–9 in Denver, and said phase 3 results for its candidate are expected in the fourth quarter. Why it matters: the field's main annual data event is a month away; the in-window news is mostly announcements of what will be shown there. | | Oct 8 A search of the Federal Register found the newest FDA document mentioning steatohepatitis is a January 27, 2026 patent-term notice for resmetirom; no new agency action appeared from September 30 onward. Why it matters: the two accelerated approvals described below remain the governing drug labels. | | | Before anything else The federal medical encyclopedia advises emergency help for vomiting blood or rectal bleeding, confusion or a change in alertness, abdominal swelling that is new or suddenly worse, and jaundice that is new or worsens quickly. It separately lists black, tarry stools and vomit that looks like coffee grounds as reasons to call 911. These are signs of advanced disease or bleeding, not of early fat in the liver, and a screening score has no role once they appear. No prescribed medication should be started, stopped or changed except with the prescriber. | | | | Why the Name Changed in 2023 | The old terms were nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. A process led by the American, European, Latin American and Asian Pacific liver associations replaced them in June 2023 after a multi-round survey of more than 200 experts; about 85% ultimately approved the recommendation, according to the American association. The new umbrella term is steatotic liver disease. Within it, metabolic dysfunction-associated steatotic liver disease, abbreviated MASLD, requires liver fat plus at least one of five cardiometabolic criteria. Those are a body mass index of 25 or more, or 23 in Asian populations, or an elevated waist measurement; elevated fasting glucose, an A1c of 5.7% or more, or diabetes; blood pressure of 130/85 or higher or treatment; elevated triglycerides or treatment; and low HDL cholesterol or treatment. The renaming changed the definition from an exclusion to an inclusion. The old name described what the disease was not; the new one names the metabolic dysfunction that is present. A separate category, MetALD, covers people who meet the metabolic criteria and drink more than 140 grams of alcohol a week for women or 210 grams for men. The inflammatory form, formerly NASH, is now MASH. | By the numbers | | 1 of 5 | Cardiometabolic criteria required, with liver fat, for the new diagnosis | | 24% | American adults estimated to have the condition, national institute | | 1.5–6.5% | American adults estimated to have the inflammatory form | | >70% | Share of Americans with type 2 diabetes affected, diabetes association | | 1.3 | FIB-4 score below which advanced scarring is unlikely | | 2.67 | FIB-4 score above which advanced scarring is likely | | 8 kPa | Liver stiffness below which advanced scarring is excluded on elastography | | | | How the Four-Number Score Is Calculated | FIB-4 is a ratio. A university hepatitis program's calculator states the formula as age multiplied by the enzyme AST, divided by the platelet count multiplied by the square root of the enzyme ALT. Age is in years, both enzymes in units per liter, and platelets in billions per liter. The score was first validated in hepatitis C, where that calculator still uses cutoffs of 1.45 and 3.25. Liver-disease guidance for the metabolic form uses 1.3 and 2.67. The American association's fellow network summarizes the 2023 practice guidance: below 1.3 is low risk and can be followed in primary care; 1.3 or higher calls for a second test; above 2.67 makes advanced fibrosis likely. Age changes the reading. For people over 65, the same summary uses 2.0 as the lower threshold, and for people under 35 it calls the score less reliable and recommends an additional test. The American Diabetes Association's 2025 consensus report goes further on who should be checked: "Consider screening all individuals with prediabetes and type 2 diabetes for MASLD." It recommends repeating the score every one to two years when it is below 1.3, and states that the condition "affects over 70% of individuals with type 2 diabetes in the US." That overlap is why a diabetes body, and not only the liver societies, now publishes screening advice for the liver. | | 🩹 Health Stat of the Day 1.3 The FIB-4 score below which advanced liver scarring is considered unlikely, according to liver and diabetes guidance for the metabolic form of fatty liver disease. A score at or above it leads to a stiffness scan or a blood fibrosis panel. The inputs — age, AST, ALT and platelets — come from a routine metabolic panel and blood count, so the score can be calculated without a new test. | | | | What the Scan Adds and What the Labels Require | The second step is usually vibration-controlled transient elastography, a scan that measures liver stiffness in kilopascals. In the American association's summary, below 8 is low risk, 8 to 12 intermediate and above 12 high. The diabetes association's report treats a reading above 8 as grounds for referral to a liver specialist. MRI-based tests and biopsy are reserved for uncertain or high-risk results. Treatment is defined by the labels. FDA's March 14, 2024 approval of resmetirom covers adults with the inflammatory form and moderate to advanced scarring, without cirrhosis, as an add-on to diet and exercise. In its trial of 888 patients, resolution without worsening scarring at 12 months ranged from 24% to 36% on the drugs against 9% to 13% on placebo, depending on the pathologist reading the biopsies. Semaglutide received accelerated approval for the same population on August 15, 2025, with a reduced-calorie diet and increased physical activity. At 72 weeks, steatohepatitis resolved without worsening fibrosis in 63% on the drug against 34% on placebo. Both approvals rest on biopsy findings rather than outcomes such as cirrhosis or death; confirmatory trials continue. Whether either drug suits a given patient is a decision for the prescriber. | Where the liver rules are written | | Multisociety nomenclature | Steatotic liver disease, MASLD, MetALD and MASH replace the old termsAnnounced June 2023 | | Diabetes association consensus | Screen prediabetes and type 2 diabetes with FIB-4, then elastographyDiabetes Care, July 2025 | | FDA, resmetirom | Noncirrhotic disease with moderate to advanced scarring, with diet and exerciseAccelerated approval March 14, 2024 | | FDA, semaglutide | Same population, with reduced-calorie diet and activityAccelerated approval August 15, 2025 | | One question for the desk Has a recent blood panel ever been turned into a FIB-4 score during a checkup? Hit reply — one line is enough. | | Worth stating plainly Fatty liver disease now carries a metabolic name and a defined screening path. The first step is a FIB-4 score from routine blood tests, the second a stiffness scan when the score is not low, and two drugs hold accelerated approval for the inflammatory form with scarring. Bleeding, confusion, jaundice and new abdominal swelling require emergency care. | | The short checklist | 1. | Seek emergency care for vomiting blood, black stools, confusion, new abdominal swelling or yellowing skin or eyes. | | 2. | Ask whether recent blood work supports a FIB-4 calculation, especially with diabetes or prediabetes. | | 3. | Note the cutoffs: below 1.3 low, above 2.67 likely advanced; different thresholds apply over 65. | | 4. | Expect elastography, not biopsy, as the usual second step. | | 5. | Leave any medication decision to the prescriber. | | | | | Replies to this briefing reach a person, not a queue. Connor Hill reads every reply. | | | Sources checked Verified October 08, 2026 American Association for the Study of Liver Diseases, new MASLD nomenclature page, and Liver Fellow Network, noninvasive assessment summary, December 17, 2023 American Diabetes Association, consensus report on MASLD in people with diabetes, Diabetes Care, July 2025 National Institute of Diabetes and Digestive and Kidney Diseases, definition and facts for NAFLD and NASH; MedlinePlus, cirrhosis and gastrointestinal bleeding pages Food and Drug Administration, press announcement on resmetirom, March 14, 2024; Consultant360 report on semaglutide approval for MASH, August 2025 CHESS-LiverHealth study in The Lancet Gastroenterology and Hepatology, as reported October 4–5, 2026; Pharmacy Times on the STEP UP liver analysis, October 6, 2026 University of Washington hepatitis program, FIB-4 calculator; Federal Register document search, October 8, 2026 Connor Hill writes The Hill Report for InsightfulWord, a daily briefing on the machinery behind the numbers. |
